| Website | actbiotech.com |
| Category | BioTech |
| Phone | 415-230-3900 |
| Employees | |
| Description | Cancer management |
| Series A, 5/08 NGN Capital | $12M |
ACT Biotech is uniquely positioned to bring innovative therapies to bear in managing cancer, especially in underserved disease sectors where patient need is acute. The Company’s advantages include a seasoned, international leadership team, unmatched expertise in clinical development and commercialization, and an exceptional portfolio of pre-clinical drug candidates. ACT has launched an aggressive, focused development strategy designed to accelerate delivery of therapeutic tools to respond to the needs of cancer patients. The Company’s strength and stability provide unique opportunities for corporate partnerships to help advance its portfolio of promising, validated drug compounds.
